Every inpatient needs VTE risk assessment. Padua score for medical patients. Caprini score for surgical. Pharmacologic (LMWH preferred) unless contraindicated. Mechanical (SCDs) if bleeding risk. "Did you order the DVT ppx?" -yes, always.
VTE prophylaxis is one of the most impactful things you order every day. Hospital-acquired VTE is preventable. Not ordering prophylaxis is a patient safety event.
Key Evidence: Enoxaparin 40 mg daily reduced VTE by 63% in acutely ill medical patients MEDENOX, 1999. Dalteparin reduced VTE in medical patients PREVENT, 2004. Fondaparinux reduced VTE in medical patients ARTEMIS, 2006. Extended post-discharge prophylaxis with rivaroxaban did not significantly reduce symptomatic VTE MARINER, 2018.
Special Populations
Population
Recommendation
Notes
Pregnancy
Enoxaparin preferred; avoid warfarin
Increased VTE risk in pregnancy + postpartum. Warfarin is teratogenic (crosses placenta).
Extended prophylaxis: Continue ร 35 days post-op (not just until discharge).
At discharge: May switch to rivaroxaban 10 mg PO daily for convenience.
Key lesson: Hip and knee replacement require extended prophylaxis ร 35 days. VTE risk persists well beyond hospitalization. Standard 10โ14 days is insufficient.
๐ Case 3, CKD Patient (LMWH Contraindicated)
Patient: 68M with CKD stage 4 (CrCl 22 mL/min), admitted for CHF exacerbation.
Why LMWH is contraindicated: Enoxaparin is renally cleared. CrCl < 30 โ drug accumulates โ bleeding risk.
Order:
Heparin 5,000 units SC q8h (hepatic metabolism, not renally cleared)
SCDs (combination prophylaxis for added protection)
Key lesson: Always check CrCl before ordering enoxaparin. CrCl < 30 = use UFH. This is one of the most common prophylaxis errors on wards.
๐จ Management
Prophylaxis Options
Method
Option
Dose
Pharmacologic (preferred)
Enoxaparin (Lovenox)
40 mg SC daily (or 30 mg SC q12h if BMI > 40 or CrCl < 30 โ use UFH)
Heparin (unfractionated)
5,000 units SC q8h (preferred if CrCl < 30 or high bleed risk -shorter half-life)
Mechanical
SCDs (sequential compression devices)
Both legs, worn whenever in bed
Extended prophylaxis
Rivaroxaban (Xarelto) or Enoxaparin (Lovenox)
Post-discharge for high-risk medical (MARINER) or post-surgical (hip/knee)
๐ Updated Practice: Old teaching: sequential compression devices (SCDs) are equivalent to pharmacologic VTE prophylaxis. Current practice: pharmacologic prophylaxis (enoxaparin 40 mg SQ daily or heparin 5000 units SQ q8-12h) is superior to mechanical prophylaxis alone. SCDs should be used only when pharmacologic prophylaxis is contraindicated (active bleeding, severe thrombocytopenia). The combination of both is used in highest-risk patients (trauma, major orthopedic surgery).
Extended Prophylaxis Evidence: Hip/knee replacement: Extended prophylaxis x 35 days reduces VTE by ~60% RECORD, 2008. Cancer surgery: Extended LMWH x 4 weeks post-op reduces VTE ENOXACAN II, 2002. Medical patients: Extended prophylaxis NOT routinely recommended APEX, 2016EXCLAIM, 2010.
Contraindications to Pharmacologic Prophylaxis
Active bleeding
Severe thrombocytopenia (platelets < 50K)
Recent intracranial hemorrhage
Epidural/spinal anesthesia (hold LMWH around procedure)
HIT (heparin-induced thrombocytopenia) -use mechanical only or argatroban if treatment-dose needed
๐งช Workup
Padua Score (medical) or Caprini Score (surgical) -on admission
IMPROVE Bleed Score -if considering pharmacologic
Platelet count -< 50K โ mechanical only
Creatinine/CrCl -CrCl < 30 โ use UFH instead of LMWH
Review medications -anticoagulants already on board?
๐ Medications
Drug
Dose
Key Notes
Enoxaparin (Lovenox)
40 mg SC daily
Preferred LMWH. Predictable pharmacokinetics. No monitoring needed.
Heparin (UFH)
5,000 units SC q8h
Use if CrCl < 30, high bleed risk (shorter half-life), or obese patients.
Fondaparinux (Arixtra)
2.5 mg SC daily
Alternative if HIT. Factor Xa inhibitor. Renally cleared.
๐ On Rounds
Pimp Questions
Why is q8h UFH preferred over q12h for VTE prophylaxis?
Multiple meta-analyses show that 5,000 units SC q8h (TID) is superior to q12h (BID) for preventing VTE in medical patients. The difference is particularly significant for DVT prevention. Q8h maintains more consistent anti-Xa levels. The trade-off is slightly higher minor bleeding risk, but the VTE prevention benefit outweighs this.
When should you use UFH instead of LMWH for prophylaxis?
(1) CrCl < 30 mL/min -LMWH is renally cleared and accumulates โ bleeding risk. UFH is metabolized by the reticuloendothelial system. (2) High bleeding risk -UFH has a shorter half-life (1โ2h vs 4โ5h for LMWH), so effects wear off faster if bleeding occurs. (3) Planned procedures -easier to manage perioperatively. (4) Morbid obesity -some guidelines recommend UFH q8h or adjusted LMWH dosing (enoxaparin 40 mg q12h for BMI > 40).
Why is LMWH preferred over UFH for VTE prophylaxis?
LMWH has more predictable pharmacokinetics, longer half-life allowing once daily dosing (vs q8h for UFH), lower risk of HIT, and no need for aPTT monitoring. RCTs have shown LMWH is at least as effective as UFH for VTE prevention. UFH is preferred only when LMWH is contraindicated: CrCl < 30 (LMWH accumulates), high bleed risk (shorter half-life advantage), or perioperative setting (easier to hold and reverse).
Should you hold DVT prophylaxis for a procedure?
Depends on the procedure and bleeding risk. LMWH: hold 12h before and resume 12h after low-bleed-risk procedures. For high-bleed-risk procedures: hold 24h before. UFH: hold 4โ6h (shorter half-life is an advantage here). Neuraxial procedures (epidural/spinal): hold LMWH โฅ12h before placement and โฅ4h after catheter removal, risk of epidural hematoma is devastating.
What is the IMPROVE VTE score?
A validated risk assessment tool specifically for acutely ill medical patients that predicts 3-month VTE risk. Components: Previous VTE (+3), known thrombophilia (+2), lower limb paralysis (+2), active cancer (+2), ICU/CCU stay (+1), complete immobilization โฅ1 day (+1), age โฅ60 (+1). Score โฅ 4 = high risk โ pharmacologic prophylaxis indicated.
What did the MEDENOX trial show?
MEDENOX, 1999: Enoxaparin 40 mg daily reduced VTE in acutely ill medical patients by 63% vs placebo. Established the standard prophylactic dose of enoxaparin 40 mg SC daily. The 20 mg dose was NOT effective - only 40 mg showed benefit. Landmark trial that changed practice for medical inpatient prophylaxis.
What is the evidence for extended VTE prophylaxis after hospital discharge?
MARINER, 2018: Rivaroxaban 10 mg x 45 days post-discharge did NOT significantly reduce symptomatic VTE in acutely ill medical patients. APEX, 2016: Betrixaban showed modest benefit. Extended prophylaxis is supported for orthopedic surgery (hip/knee x 35 days) but NOT routinely for medical patients.
What is the Caprini score and how does it differ from Padua?
Caprini is for SURGICAL patients. Assigns weighted points for risk factors (prior VTE, cancer, age, surgery type, immobility). Score determines prophylaxis intensity: 0 = ambulation only, 1-2 = SCDs, 3-4 = pharmacologic, โฅ 5 = pharmacologic + extended. Padua is for MEDICAL patients with threshold โฅ 4 for pharmacologic prophylaxis.
Why is fondaparinux safe in HIT?
Fondaparinux (Arixtra) is a synthetic pentasaccharide that inhibits factor Xa. Unlike UFH and LMWH, it does NOT bind to platelet factor 4 (PF4), so it does not trigger the HIT antibody response. Can be used for prophylaxis (2.5 mg SC daily) or treatment-dose anticoagulation in confirmed HIT as an alternative to argatroban or bivalirudin.
โก Summary
Every Patient
VTE risk assessment on admission. Padua โฅ 4 (medical) or Caprini-based (surgical) โ prophylax.
First-Line
Enoxaparin 40mg SC daily. Use UFH 5000 SC q8h if CrCl < 30 or high bleed risk.